UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported): November 4, 2025~~1934

Date of Report (Date of earliest event reported): November 7, 2025

Personalis, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	~~001-38943~~	27001-~~5411038~~38943	27-5411038
(State or Other Jurisdictionof Incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)
(State or Other Jurisdiction of Incorporation)		(Commission File Number)	(IRS Employer Identification No.)
6600 Dumbarton CircleFremont, California		94555
(Address of Principal Executive Offices)		(Zip Code)

6600 Dumbarton Circle

Fremont, California

94555

(Address of Principal Executive Offices)

(Zip Code)

(650) 752-1300

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		TradingSymbol(s)		Name of each ~~exchange~~exchangeon on which registered
Common Stock, $0.0001 par value per share		PSNL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 28.0201 ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On November 4 7, 2025, ~~Personalis,~~our ~~Inc.~~ultrasensitive ~~issued~~NeXT aPersonal® ~~press~~test ~~release~~received ~~announcing~~Medicare ~~its~~coverage ~~financial~~for ~~results~~post-treatment ~~for~~surveillance of cancer recurrence in patients with stage II and III breast cancer. This coverage determination from the ~~quarter~~Centers ~~ended~~for ~~September~~Medicare & 30Medicaid Services Molecular Diagnostics Program is effective retroactively as of October 7, 2025., ~~The~~at ~~full~~a ~~text~~reimbursement rate of $3,878 for the ~~press~~NeXT ~~release~~Personal isDx ~~furnished~~Breast asMRD ~~Exhibit~~Recurrence ~~99.~~Monitoring Test and $1,158 tofor ~~this~~the ~~report~~NeXT onPersonal ~~Form~~Single 8Plasma Test. Medicare coverage for the NeXT Personal Single Plasma Test is available for a period of up to six years post-Ktreatment. ~~and~~Coverage for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test is ~~incorporated~~available ~~herein~~once byper ~~reference~~cancer diagnosis.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitNumber		Description
99.1		Press release of Personalis, Inc., dated November 4, 2025.
104		Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 4, 2025	Personalis, Inc.
Date: November 10, 2025			Personalis, Inc.
	~~By:~~	~~/s/ Aaron Tachibana~~	By:	/s/ Aaron Tachibana
		~~Aaron Tachibana~~		Aaron Tachibana
		~~Chief Financial Officer and Chief Operating Officer~~		Chief Financial Officer and Chief Operating Officer

Filing Compare · Personalis, Inc.